Brief: Disc Medicine Announces Success On All Primary And Secondary Endpoints In The Pivotal Phase 3 Apollo Trial Of Bitopertin In Adults And Adolescents With Erythropoietic Protoporphyria (Epp)
BRIEF-Disc Medicine Announces Success On All Primary And Secondary Endpoints In The Pivotal Phase 3 Apollo Trial Of Bitopertin In Adults And Adolescents With Erythropoietic Protoporphyria (Epp) Oct 19 (Reuters) - Disc Medicine, Inc. IRON.O:
DISC MEDICINE ANNOUNCES SUCCESS ON ALL PRIMARY AND SECONDARY ENDPOINTS IN THE PIVOTAL PHASE 3 APOLLO TRIAL OF BITOPERTIN IN ADULTS AND ADOLESCENTS WITH ERYTHROPOIETIC PROTOPORPHYRIA (EPP)
DISC MEDICINE - APOLLO PHASE 3 TRIAL SHOWS STATISTICALLY SIGNIFICANT BENEFIT ACROSS ALL ENDPOINTS
DISC MEDICINE - ALL SECONDARY ENDPOINTS POSITIVE INCLUDING REDUCED PHOTOTOXIC REACTIONS AND IMPROVED LIGHT TOLERANCE
DISC MEDICINE - BITOPERTIN GENERALLY WELL-TOLERATED WITH NO NEW SAFETY SIGNALS IN APOLLO
DISC MEDICINE - PLANS NDA RESUBMISSION TO FDA BY END OF 2026, DECISION EXPECTED MID-2027
DISC MEDICINE - BITOPERTIN ACHIEVES -41.4% REDUCTION IN PPIX VERSUS PLACEBO IN APOLLO TRIAL
DISC MEDICINE - APOLLO TRIAL MEETS CO-PRIMARY ENDPOINTS OF PPIX REDUCTION AND INCREASED TIME IN LIGHT
Source text: ID:nGNXb8pMt6
Further company coverage: IRON.O
((Reuters.Briefs@thomsonreuters.com;))